ALAntonio Carlos Pedroso de Lima

Antonio Carlos Pedroso de Lima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antonio Carlos Pedroso de Lima has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A review of cost-effectiveness analysis: From theory to clinical practice

    by Sara Rn Michelly Gonçalves Brandão, Hans-Peter Brunner-La Rocca, Antonio Carlos Sc Pedroso de Lima, Edimar Alcides Bocchi

    Cost-effectiveness analysis has long been practiced; registries date back to the United States of America War Department in 1886. In addition, everyone does intuitive cost-effectiveness analyses in their daily lives. In routine medical care, health economic assessment becomes increasingly important due to progressively limited resources, rising demands, population increases, and continuous therapeutic innovations. The health economic assessment must analyze the outcomes and costs of actions and technologies as objectively as possible to guarantee efficient assessment of novel interventions for Public Health Policy. In other words, it is necessary to determine how much society or patients are willing to or able to pay for novel interventions compared with existing alternatives, given the available resources. In addition, increased cost may displace other health care services already provided in case of fixed budget health care systems. To conduct such analyses, researchers must use standard methodologies and interpretations in light of regional characteristics according to social and economic determinants as well as clinical practice. Such an approach may be essential for transforming the current healthcare system to a value-based model. In this narrative review, concepts of the importance of and some approaches to health economic evaluation in clinical practice will be discussed.


  • Destructive power series long-term survival model with complex activation schemes

    by Diego I. Gallardo, Heleno Bolfarine, Antonio C. Pedroso-De-Lima, Jose S. Romeo


  • Open Access

    Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial

    by Sara Michelly Gonçalves Brandão, Paulo Cury Rezende, Hans-Peter Brunner-La Rocca, Yang Ting Ju, Antonio Carlos Pedroso de Lima, Myrthes Emy Takiuti, Whady Hueb, Edimar Alcides Bocchi

    Background: The costs for treating coronary artery disease (CAD) are high worldwide. We performed a prespecified analyses of cost-effectiveness of three therapeutic strategies for multivessel CAD.Methods: From May 1995 to May 2000, a total of 611 patients were randomly assigned to coronary artery bypass graft (CABG), n = 203; percutaneous coronary intervention (PCI), n = 205; or medical treatment (MT), n = 203. This cost analysis study was based on the perspective of the Public Health Care System. Initial procedural and follow-up costs for medications, cardiology examinations, and hospitalizations for complications were calculated after randomization. Life-years and quality-adjusted life years (QALYs) were used as effectiveness measures. Incremental cost-effectiveness ratios (ICER) were obtained by using nonparametric bootstrapping methods with 5000 resamples.Results: Initial procedural costs were lower for MT. However, the subsequent 5-year cumulative costs were lower for CABG. Compared with baseline, the three treatment options produced significant improvements in QALYs. After 5 years, PCI and CABG had better QALYs results compared with MT. The ICER results favored CABG and PCI, and favored PCI over CABG in 61% of the drawings. On the other hand, sensitivity analysis showed MT as the preferred therapy compared with CABG and PCI, in the analysis considering higher costs.Conclusions: At 5-year follow-up, the three treatment options yielded improvements in quality of life, with comparable and acceptable costs. However, despite higher initial costs, the comparison of cost-effectiveness after 5 years of follow-up among the three treatments showed both interventions (CABG and PCI) to be cost-effective strategies compared with MT.Trial registrationISRCTN, ISRCTN66068876, Registered 06/10/1994,http://www.controlled-trials.com/ISRCTN66068876


  • Pericytes Extend Survival of ALS SOD1 Mice and Induce the Expression of Antioxidant Enzymes in the Murine Model and in IPSCs Derived Neuronal Cells from an ALS Patient

    by Giuliana Castello Coatti, Miriam Frangini, Marcos C. Valadares, Juliana Plat Gomes, Natalia O. Lima, Natale Cavaçana, Amanda F. Assoni, Mayra V. Pelatti, Alexander Birbrair, Antonio Carlos Pedroso de Lima, et al.

    Abstract Amyotrophic Lateral Sclerosis (ALS) is one of the most common adult-onset motor neuron disease causing a progressive, rapid and irreversible degeneration of motor neurons in the cortex, brain stem and spinal cord. No effective treatment is available and cell therapy clinical trials are currently being tested in ALS affected patients. It is well known that in ALS patients, approximately 50% of pericytes from the spinal cord barrier are lost. In the central nervous system, pericytes act in the formation and maintenance of the blood-brain barrier, a natural defense that slows the progression of symptoms in neurodegenerative diseases. Here we evaluated, for the first time, the therapeutic effect of human pericytes in vivo in SOD1 mice and in vitro in motor neurons and other neuronal cells derived from one ALS patient. Pericytes and mesenchymal stromal cells (MSCs) were derived from the same adipose tissue sample and were administered to SOD1 mice intraperitoneally. The effect of the two treatments was compared. Treatment with pericytes extended significantly animals survival in SOD1 males, but not in females that usually have a milder phenotype with higher survival rates. No significant differences were observed in the survival of mice treated with MSCs. Gene expression analysis in brain and spinal cord of end-stage animals showed that treatment with pericytes can stimulate the host antioxidant system. Additionally, pericytes induced the expression of SOD1 and CAT in motor neurons and other neuronal cells derived from one ALS patient carrying a mutation in FUS. Overall, treatment with pericytes was more effective than treatment with MSCs. Our results encourage further investigations and suggest that pericytes may be a good option for ALS treatment in the future. ᅟ


  • Open Access

    Beta-2 adrenergic receptor gene polymorphisms Gln27Glu, Arg16Gly in patients with heart failure

    by Alfredo José Mansur, Rosana Seleri Fontes, Regina Airoldi Canzi, Raphael Nishimura, Airlane Pereira Alencar, Antonio Carlos Pedroso de Lima, José Eduardo Krieger, Alexandre Costa Pereira

    Background -: Beta-2 adrenergic receptor gene polymorphisms Gln27Glu, Arg16Gly and Thr164Ile were suggested to have an effect in heart failure. We evaluated these polymorphisms relative to clinical characteristics and prognosis of alarge cohort of patients with heart failure of different etiologies. Methods -: We studied 501 patients with heart failure of different etiologies. Mean age was 58 years (standard deviation 14.4 years), 298 (60%) were men. Polymorphisms were identified by polymerase chain reaction-restriction fragment length polymorphism. Results -: During the mean follow-up of 12.6 months (standard deviation 10.3 months), 188 (38%) patients died. Distribution of genotypes of polymorphism Arg16Gly was different relative to body mass index (χ2 = 9.797;p = 0.04). Overall the probability of survival was not significantly predicted by genotypes of Gln27Glu, Arg16Gly, or Thr164Ile. Allele and haplotype analysis also did not disclose any significant difference regarding mortality. Exploratory analysis through classification trees pointed towards a potential association between the Gln27Glu polymorphism and mortality in older individuals. Conclusion -: In this study sample, we were not able to demonstrate an overall influence of polymorphisms Gln27Glu and Arg16Gly of beta-2 receptor gene on prognosis. Nevertheless, Gln27Glu polymorphism may have a potential predictive value in older individuals.


  • A semi-Markov multistate model for estimation of the mean quality-adjusted survival for non-progressive processes

    by Gisela Tunes-Da-Silva, Antonio C. Pedroso-De-Lima, Pranab K. Sen

    We discuss the estimation of the expected value of the quality-adjusted survival, based on multistate models. We generalize an earlier work, considering the sojourn times in health states are not identically distributed, for a given vector of covariates. Approaches based on semiparametric and parametric (exponential and Weibull distributions) methodologies are considered. A simulation study is conducted to evaluate the performance of the proposed estimator and the jackknife resampling method is used to estimate the variance of such estimator. An application to a real data set is also included.


  • Cure Rate Model with Measurement Error

    by Marcia F. Mizoi, Heleno Bolfarine, Antonio C. Pedroso-De-Lima

    Censoring is a common feature in survival data, usually associated with loss to follow-up. However, when the fraction of censored data is high, it may indicate that part of the experimental units are no longer at risk of presenting the event of interest. In this article we consider the approach of Chen et al. ( 1999 Chen , M.-H. , Ibrahim , J. G. , Sinha , D. ( 1999 ). A new Bayesian model for survival data with a surviving fraction . Journal of the American Statistical Association 94 : 909 – 919 . [Taylor & Francis Online], [Web of Science ®] [Google Scholar] ) for such situation, and discuss the case where covariates may be measured with error. Simulations and an application to a real dataset are also presented.


  • Bivariate survival modeling: a Bayesian approach based on Copulas

    by José S. Romeo, Nelson I. Tanaka, Antonio C. Pedroso-De-Lima

    Copula models have become increasingly popular for modeling multivariate survival data. In this paper we review some of the recent work that has been appeared for copula model for bivariate survival data and propose a Bayesian modeling. Our approach is very flexible with respect to the choice of marginal distributions and, depending on the copula model employed, it is possible to have a class of variation for the dependence parameter. We compare some of the copula models using a descriptive diagnostic method and three popular Bayesian model selection criteria. Our methodology is illustrated with the Diabetic Retinopathy Study (1976).